

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China NT Pharma Group Company Limited**

**中國泰凌醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 01011)**

### **CHANGE OF AUDITORS**

The board (the “**Board**”) of directors of the Company (the “**Directors**”) announces that KPMG has resigned as auditors of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) with effect from 10 January 2014.

The Board further announces that the Company has appointed Crowe Horwath (HK) CPA Limited as the new auditors of the Company with effect from 10 January 2014 to fill the casual vacancy following the resignation of KPMG and to hold office until the conclusion of the next annual general meeting of the Company.

The Board announces that KPMG has resigned as auditors of the Company with effect from 10 January 2014, as the Company could not reach an agreement with KPMG on the Company’s request for a reduction to the audit fees payable to KPMG for the year ended 31 December 2013. The Board further announces that the Company has appointed Crowe Horwath (HK) CPA Limited as the new auditors of the Company with effect from 10 January 2014 to fill the casual vacancy following the resignation of KPMG and to hold office until the conclusion of the next annual general meeting of the Company.

The following matters should be brought to the attention of the shareholders of the Company:

1. KPMG were re-appointed as auditors of the Company at the annual general meeting of the Company held on 21 June 2013 and commenced certain audit work from September 2013 in relation to the financial year ended 31 December 2013. KPMG reported the audit progress and preliminary findings to the audit committee of the Company on 19 December 2013 but had not completed the audit for the financial year ended 31 December 2013; and

2. In their audit report dated 28 March 2013 for the financial year ended 31 December 2012, KPMG expressed a qualified opinion arising from limitation of scope, details of which are set out in the Company's 2012 annual report.

Other than the above matters, the letter of resignation received by the Company from KPMG confirms that no other matters need to be brought to the attention of the shareholders of the Company. The Board also confirms that there are no other matters and circumstances in respect of the change of auditors which it considers should be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to thank KPMG for its professional services and support to the Company during the past years.

By order of the Board  
**China NT Pharma Group Company Limited**  
**Ng Tit**  
*Chairman*

Hong Kong, 10 January 2014

*As at the date of this announcement, the executive director of the Company is Mr. Ng Tit; the non-executive directors of the Company are Ms. Chin Yu, Dr. Qian Wei, Mr. Wang Fan and Mr. Hung Leung; and the independent non-executive directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.*